ClinicalTrials.gg

Program

baricitinib

Also written as “Baricitinib”, “LY3009104” and “INCB028050”.

Its studies are mostly in Arthritis, Rheumatoid · Dermatitis, Atopic · Lupus Erythematosus, Systemic · COVID-19 · Arthritis, Juvenile, led by 5 companies.

Furthest: phase 4, since Apr 12, 201958 company-led studies, 7 open or runningNext primary completion: Jul 2027

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly546 open or runningphase 4since Apr 12, 2019Aug 18, 2010Mar 2028phase 3 · NCT05723198
Galvani Bioelectronics11 open or runningno phasesince Jul 5, 2021Jul 5, 2021Jul 2027NCT05003310
Genuine Research Center, Egypt10 open or runningphase 1since Aug 9, 2021Aug 9, 2021none ahead
Incepta Pharmaceuticals10 open or runningphase 3since Sep 20, 2021Sep 20, 2021none ahead
Incyte10 open or runningphase 2since May 13, 2009May 13, 2009none ahead

Also a collaborator on its studies: q2-solutions and horus-pharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 42 studies since May 13, 2009.

  1. Feb 14, 2019Phase 3 study in Lupus Erythematosus, SystemicEli Lilly · NCT03843125 · 1,147 enrolled · United States, Argentina, Australia and more
  2. Apr 1, 2019Phase 3 study in Alopecia AreataEli Lilly · NCT03899259 · 606 enrolled · United States, Argentina, Australia and more
  3. Apr 12, 2019Phase 4 study in Arthritis, RheumatoidEli Lilly · NCT03915964 · 2,659 enrolled · United States, Australia, Austria and more
  4. May 15, 2019Phase 3 study in Dermatitis, AtopicEli Lilly · NCT03952559 · 516 enrolled · Argentina, Australia, Austria and more
  5. Sep 10, 2019Phase 4 study in Arthritis, RheumatoidEli Lilly · NCT04086745 · 1,050 enrolled · United States
  6. Sep 11, 20192 phase 3 studiesEli Lilly · NCT04088409, NCT04088396
  7. Jun 5, 2020Phase 3 study in COVID-19Eli Lilly · NCT04421027 · 1,525 enrolled · United States, Argentina, Brazil and more
  8. Aug 17, 2020Phase 3 study in Nakajo syndromeEli Lilly · NCT04517253 · 10 enrolled · Japan
  9. Jul 5, 2021Galvani Bioelectronics's first study: no phase study in Arthritis, RheumatoidNew to Galvani BioelectronicsGalvani Bioelectronics · NCT05003310 · 28 planned · United States, Netherlands
  10. Aug 9, 2021Genuine Research Center, Egypt's first study: phase 1 study in HealthyNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT05006768 · 30 enrolled · Egypt
  11. Sep 20, 2021Incepta Pharmaceuticals's first study: phase 3 study in COVID-19New to Incepta PharmaceuticalsIncepta Pharmaceuticals · NCT05056558 · Bangladesh
  12. Oct 8, 2021Phase 3 study in COVID-19Eli Lilly · NCT05074420 · 6 enrolled · United States, Brazil, Mexico and more
  13. Feb 3, 2023Phase 3 study in AlopeciaEli Lilly · NCT05723198 · 595 planned · United States, Argentina, Australia and more
  14. Oct 27, 20252 phase 3 studies in Diabetes Mellitus, Type 1Eli Lilly · NCT07222332, NCT07222137

Ahead

  1. Jul 2027Primary completion: no phase study in Arthritis, RheumatoidGalvani Bioelectronics · NCT05003310
  2. Mar 2028Primary completion: phase 3 study in AlopeciaEli Lilly · NCT05723198
  3. Jul 2028Primary completion: phase 3 study in Diabetes Mellitus, Type 1Eli Lilly · NCT07222332
  4. Jul 2031Primary completion: phase 3 study in Diabetes Mellitus, Type 1Eli Lilly · NCT07222137

TargetBeta

JAK1 →JAK2 →read by rule
“An orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), ”NCIt, by rule
“Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
ruxolitinibruleIncytephase 495
tofacitinibrulePfizerphase 494
upadacitinibruleAbbViephase 464
filgotinib maleateruleEisaiphase 42
filgotinibruleLakefront Biotherapeutics NVphase 346
jaktinibruleSuzhou Zelgen Biopharmaceuticalsphase 331
delgocitinibruleLEO Pharmaphase 321
momelotinibruleGlaxoSmithKlinephase 317

Studies

All 58 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07222332Diabetes Mellitus, Type 1 · United States, Australia, Belgium and more3RecruitingEli LillyJul 2028300
NCT07222137Diabetes Mellitus, Type 1 · United States, Australia, Belgium and more3RecruitingEli LillyJul 2031150
NCT05723198Alopecia · United States, Argentina, Australia and more3RecruitingEli LillyMar 2028595
NCT05074420COVID-19 · United States, Brazil, Mexico and more3TerminatedEli LillySep 5, 20246
NCT05056558COVID-19 · Bangladesh3WithdrawnIncepta PharmaceuticalsJul 30, 20250
NCT05006768Healthy · Egypt1CompletedGenuine Research Center, EgyptJun 3, 202130
NCT05003310Arthritis, Rheumatoid · United States, Netherlands–RecruitingGalvani BioelectronicsJul 202728
NCT04517253Nakajo syndrome · Japan3TerminatedEli LillyApr 4, 202310
NCT04421027COVID-19 · United States, Argentina, Brazil and more3CompletedEli LillyFeb 12, 20211,525
NCT04088409Uveitis · France, Germany, Italy and more3Active, not recruitingEli LillyJul 17, 202330
NCT04088396Arthritis, Juvenile · Argentina, Belgium, Brazil and more3Active, not recruitingEli LillyOct 202658
NCT04086745Arthritis, Rheumatoid · United States4CompletedEli LillyMay 19, 20251,050
NCT03952559Dermatitis, Atopic · Argentina, Australia, Austria and more3CompletedEli LillyApr 24, 2022516
NCT03915964Arthritis, Rheumatoid · United States, Australia, Austria and more4CompletedEli LillyMay 28, 20252,659
NCT03899259Alopecia Areata · United States, Argentina, Australia and more3CompletedEli LillyJan 24, 2021606
NCT03843125Lupus Erythematosus, Systemic · United States, Argentina, Australia and more3TerminatedEli LillyApr 1, 20221,147
NCT03773978Arthritis, Juvenile · Argentina, Australia, Austria and more3CompletedEli LillyJan 26, 2022220
NCT03773965Arthritis, Juvenile · Argentina, Australia, Austria and more3RecruitingEli LillyJul 2031190
NCT03742973Liver Cirrhosis, Biliary · United States, Puerto Rico2TerminatedEli LillySep 26, 20192
NCT03733301Dermatitis, Atopic · Argentina, Australia, Austria and more3CompletedEli LillyJul 29, 2019329
NCT03616964Lupus Erythematosus, Systemic · United States, Argentina, Chile and more3CompletedEli LillySep 24, 2021778
NCT03616912Lupus Erythematosus, Systemic · United States, Australia, Austria and more3TerminatedEli LillyNov 1, 2021830
NCT03570749Alopecia Areata · United States, Japan, Mexico and more3CompletedEli LillyFeb 2, 2021784
NCT03559270Dermatitis, Atopic · United States, Canada, Puerto Rico3TerminatedEli LillyOct 14, 2021374
NCT03435081Dermatitis, Atopic · United States, Canada, Puerto Rico3CompletedEli LillyDec 9, 2019440
NCT03428100Dermatitis, Atopic · Austria, Belgium, Brazil and more3CompletedEli LillyNov 25, 2019463
NCT03334435Dermatitis, Atopic · Argentina, Australia, Austria and more3CompletedEli LillySep 21, 20201,645
NCT03334422Dermatitis, Atopic · Argentina, Australia, Austria and more3CompletedEli LillyDec 12, 2018615
NCT03334396Dermatitis, Atopic · Czechia, Denmark, France and more3CompletedEli LillyDec 6, 2018660
NCT03212638Healthy · Singapore1CompletedEli LillyJul 31, 201742
NCT02758613Healthy · China1CompletedEli LillyJul 201633
NCT02708095Lupus Erythematosus, Systemic · United States, Argentina, Austria and more2CompletedEli LillyOct 12, 2017314
NCT02576938Dermatitis, Atopic · United States, Japan2CompletedEli LillyFeb 2017124
NCT02340104Healthy Volunteers · United Kingdom1CompletedEli LillyFeb 20158
NCT02265705Arthritis, Rheumatoid · Argentina, Brazil, China3CompletedEli LillyMay 2017290
NCT02263911Healthy Participants · Japan1CompletedEli LillyDec 201416
NCT01968057Healthy Volunteers · United Kingdom1CompletedEli LillyDec 201318
NCT01937026Healthy Volunteers · United Kingdom1CompletedEli LillyNov 201318
NCT01925144Healthy Volunteers · United Kingdom1CompletedEli LillyNov 201330
NCT01924299Healthy Volunteers · United Kingdom1CompletedEli LillyNov 201336
NCT01910311Healthy Volunteers · United Kingdom1CompletedEli LillyOct 201318
NCT01896726Healthy Volunteers · United Kingdom1CompletedEli LillyOct 201320
NCT01885078Arthritis, Rheumatoid · United States, Argentina, Australia and more3CompletedEli LillyNov 12, 20202,877
NCT01870388Liver Diseases · United States1CompletedEli LillyJul 201316
NCT01859078Healthy Volunteers · United Kingdom1CompletedEli LillyAug 201328
NCT01721057Arthritis, Rheumatoid · United States, Argentina, Australia and more3CompletedEli LillySep 2014684
NCT01721044Arthritis, Rheumatoid · United States, Argentina, Australia and more3CompletedEli LillyJun 2014527
NCT01711359Arthritis, Rheumatoid · United States, Argentina, Austria and more3CompletedEli LillyFeb 2015588
NCT01710358Arthritis, Rheumatoid · United States, Argentina, Belgium and more3CompletedEli LillyMar 20151,307
NCT01683409Diabetic Nephropathies · United States, Japan, Mexico and more2CompletedEli LillySep 2014130
NCT01536951Healthy Participants · United States1CompletedEli LillyMay 201362
NCT01490632Psoriasis · United States, Canada, Japan and more2CompletedEli LillyDec 2012271
NCT01469013Arthritis, Rheumatoid · Japan2CompletedEli LillyNov 2012145
NCT01398475Arthritis, Rheumatoid · Singapore1CompletedEli LillySep 201115
NCT01299285Healthy Volunteers · United States1CompletedEli LillyMar 20116
NCT01247350Healthy Volunteer · United States1CompletedEli LillyApr 201134
NCT01185353Arthritis, Rheumatoid · United States, Croatia, Czechia and more2CompletedEli LillyDec 2011301
NCT00902486Arthritis, Rheumatoid · United States, Czechia2CompletedIncyteJun 2010127

How it is read

Names in the registry

  • “Baricitinib”, 53 entries
  • “LY3009104”, 5 entries
  • “INCB028050”, 3 entries
  • “Barcimiant”, 1 entry
  • “Baricitinib suspension”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.